6 競争状況
6.1 企業プロフィール
6.1.1 B. Braun SE
6.1.2 Baxter Healthcare Corporation
6.1.3 Dr.Reddy’s Laboratories
6.1.4 Fresenius SE & Co. KGaA
6.1.5 Hikma Pharmaceuticals
6.1.6 Pfizer Inc.
6.1.7 Piramal Enterprises Ltd.
6.1.8 Aspen Holdings
6.1.9 Eisai Inc.
6.1.10 Flagship Biotech International Pvt Ltd
7 市場機会と今後の動向
❖ レポートの目次 ❖
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 The Growing Burden of Various Brain Diseases and Injuries
4.2.2 Rise in Surgical Procedures
4.3 Market Restraints
4.3.1 Side Effects Associated with the Anesthesia Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD)
5.1 By Drug Type
5.1.1 Propofol
5.1.2 Barbiturate
5.1.3 Others
5.2 By Application
5.2.1 Status Epilepticus
5.2.2 Stroke
5.2.3 Traumatic Brain Injury
5.2.4 Brain Infections
5.2.5 Drug Overdose
5.2.6 Others
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Drug Stores & Retail Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Rest of the World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 B. Braun SE
6.1.2 Baxter Healthcare Corporation
6.1.3 Dr.Reddy’s Laboratories
6.1.4 Fresenius SE & Co. KGaA
6.1.5 Hikma Pharmaceuticals
6.1.6 Pfizer Inc.
6.1.7 Piramal Enterprises Ltd.
6.1.8 Aspen Holdings
6.1.9 Eisai Inc.
6.1.10 Flagship Biotech International Pvt Ltd
